The global healthcare company will use the facility in North Carolina to produce active pharmaceutical ingredients for diabetes drugs
Fluor Corporation has been awarded an engineering, procurement, construction and construction management contract by Novo Nordisk for its new US$2bn diabetes Active Pharmaceutical Ingredient (API) manufacturing facility in Clayton, North Carolina.
Fluor has been providing basic design services since Novo Nordisk announced plans for the new facility in August 2015 and now will be executing the full scope of work.
Fluor booked its $1.2bn value of the investment in the fourth quarter of 2016.
“Fluor is honoured to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” said Juan G. Hernández, president of Fluor’s Life Sciences and Advanced Manufacturing business.
“This project is the single largest life sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States.”
The new facility will measure more than 830,000 ft2, the equivalent of nearly seven football fields, and will produce life-saving medicines for use by patients around the world.
Fluor participated in a groundbreaking event this past spring, and its Greenville, South Carolina office is leading the project. Construction is expected to be completed in mid-2019.
Headquartered in Irving, Texas, Fluor Corporation is a global engineering, procurement, fabrication, construction and maintenance company that operates on six continents.